ASTRAZENECA PLC-SPONS ADR (AZN) Stock Price & Overview
NYSE:AZN • US0463531089
Current stock price
The current stock price of AZN is 202.24 USD. Today AZN is down by -0.88%. In the past month the price increased by 6.5%. In the past year, price increased by 49.61%.
AZN Key Statistics
- Market Cap
- 313.641B
- P/E
- 21.91
- Fwd P/E
- 19.12
- EPS (TTM)
- 9.23
- Dividend Yield
- 1.55%
AZN Stock Performance
AZN Stock Chart
AZN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AZN. When comparing the yearly performance of all stocks, AZN is one of the better performing stocks in the market, outperforming 81.78% of all stocks.
AZN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to AZN. AZN has an excellent profitability rating, but there are some minor concerns on its financial health.
AZN Earnings
On February 10, 2026 AZN reported an EPS of 2.14 and a revenue of 15.50B. The company missed EPS expectations (-1.5% surprise) and missed revenue expectations (-2.88% surprise).
AZN Forecast & Estimates
36 analysts have analysed AZN and the average price target is 220.72 USD. This implies a price increase of 9.14% is expected in the next year compared to the current price of 202.24.
For the next year, analysts expect an EPS growth of 14.55% and a revenue growth 7.34% for AZN
AZN Groups
Sector & Classification
AZN Financial Highlights
Over the last trailing twelve months AZN reported a non-GAAP Earnings per Share(EPS) of 9.23. The EPS increased by 11.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.41% | ||
| ROA | 8.96% | ||
| ROE | 21.01% | ||
| Debt/Equity | 0.55 |
AZN Ownership
AZN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.59 | 887.63B | ||
| JNJ | JOHNSON & JOHNSON | 20.42 | 574.357B | ||
| MRK | MERCK & CO. INC. | 23.6 | 300.198B | ||
| PFE | PFIZER INC | 9.15 | 153.131B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.17 | 119.687B | ||
| ZTS | ZOETIS INC | 16.98 | 49.752B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.37 | 27.632B | ||
| VTRS | VIATRIS INC | 5.55 | 15.685B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.68 | 11.5B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.11B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.481B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.074B | ||
| CORT | CORCEPT THERAPEUTICS INC | 79.8 | 4.458B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AZN
Company Profile
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
Company Info
IPO: 2007-09-21
ASTRAZENECA PLC-SPONS ADR
1 Francis Crick Avenue, Cambridge Biomedical Campus
CAMBRIDGE CAMBRIDGESHIRE CB2 0AA GB
CEO: Pascal Soriot
Employees: 96100
Phone: 442037495000
ASTRAZENECA PLC-SPONS ADR / AZN FAQ
Can you describe the business of ASTRAZENECA PLC-SPONS ADR?
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
What is the current price of AZN stock?
The current stock price of AZN is 202.24 USD. The price decreased by -0.88% in the last trading session.
Does AZN stock pay dividends?
ASTRAZENECA PLC-SPONS ADR (AZN) has a dividend yield of 1.55%. The yearly dividend amount is currently 3.21.
How is the ChartMill rating for ASTRAZENECA PLC-SPONS ADR?
AZN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What sector and industry does ASTRAZENECA PLC-SPONS ADR belong to?
ASTRAZENECA PLC-SPONS ADR (AZN) operates in the Health Care sector and the Pharmaceuticals industry.
What is the ownership structure of ASTRAZENECA PLC-SPONS ADR (AZN)?
You can find the ownership structure of ASTRAZENECA PLC-SPONS ADR (AZN) on the Ownership tab.
What is the outstanding short interest for ASTRAZENECA PLC-SPONS ADR?
The outstanding short interest for ASTRAZENECA PLC-SPONS ADR (AZN) is 0.13% of its float.